drugset / Trial / NCT03971669

Blood Donor CVD 5000

NCT03971669

Phase 4 Recruiting 150 enrolled University of Maryland, Baltimore
NaSingle-groupOpen-labelBasic science

Summary

This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.

Timeline

Start
2004-01-16
Primary completion
2030-06-30
Completion
2030-06-30

Drugs

EvaluationDrugModalityDoseRoute
Background Vivotif Vaccine 1 unknown Oral

Indications

No indication recorded.